

# Empowering Research

## on Neurodegenerative Diseases



We are committed to advancing neurodegenerative disease diagnostics to make them more accessible to people around the world.

We're leveraging our IVD expertise and empowering cutting-edge research through:



Development of high-quality assays with exceptional sensitivity and specificity that provide confidence in your results.



Partnerships with leading clinical researchers that open the door for new assay development and accelerate new drug development.



Innovative technologies and assays—grounded in >90 years of diagnostics development—that will deliver accurate and affordable testing solutions at scale to ultimately change the paradigm of patient care.

### Blood-based Neurodegenerative Disease Assays

#### ASSAYS FOR RESEARCH USE ONLY

• p-Tau217	• $\beta$ -Amyloid 1-42*
• GFAP	• BD Tau*
• NfL	• MTBR-Tau*
• APOE $\epsilon$ 4	• TDP-43*

ASSAY HAS BEEN GRANTED BREAKTHROUGH DEVICE DESIGNATION FROM THE U.S. FDA

• p-Tau217/ $\beta$ -Amyloid 1-42 Plasma Ratio†

\*Assays in Development.

†IVD Assay in Development. Not currently for use in diagnostic procedures.

We are creating a discovery ecosystem that will enable better ways to diagnose and monitor patients to help you make informed decisions. Together, we're working to empower healthcare providers, research organizations, and laboratories to address growing diagnostic challenges.

### Why Beckman Coulter Diagnostics?

We are a global diagnostic leader in **Immunoassay, Hematology, Chemistry, Urinalysis, Microbiology, and Lab Automation** helping healthcare professionals provide better patient care.

Every hour of every day, **>1 million of our diagnostic tests are run**—impacting over 1.2 billion patients per year around the world—and our biomarker assays are unlocking more clinical insights than ever before.



**Bring the latest medical advancements to your laboratory.** An expansive suite of high performing solutions—from low-volume tabletop analyzers to high-volume automated connected systems—that provide consistent results and drive laboratory efficiency.



#### **DxI 9000 IMMUNOASSAY ANALYZER**

- Enhanced Precision: Capable of delivering down to 2 µL of sample with <2% CV
- Extended luminometer reading range with optimized signal detection at low and high levels
- Zero daily maintenance and can run up to 450 tests per hour



#### **ACCESS 2 IMMUNOASSAY ANALYZER**

- Reagent space for 24 onboard assays & up to 100 tests per hour
- Random-access analyzer, allows samples to run anytime in any combination
- Intuitive user interface

### **Beckman Coulter's comprehensive disease testing menu:**

**Anemia**

**Adrenal / Pituitary**

**Bone Metabolism**

**Cardiovascular**

**Diabetes**

**Infectious Diseases**

**Neurology**

**Prostate Health**

**Reproductive Health**

**Sepsis / Inflammation**

**Thyroid**

**Tumor Markers**

### **Proud to be part of Danaher**

We combine our capabilities to accelerate the real-life impact of tomorrow's science and technology to improve human health.



Learn more at [beckmancoulter.com/neuro](https://beckmancoulter.com/neuro)

